Publications by authors named "A Harazin-Lechowska"
Background: Colorectal cancer (CRC) prognosis is determined by the disease stage with low survival rates for advanced stages. Current CRC screening programs are mainly using colonoscopy, limited by its invasiveness and high cost. Therefore, non-invasive, cost-effective, and accurate alternatives are urgently needed.
View Article and Find Full Text PDFBladder urothelial carcinoma (BLCA) is the 10th most common cancer with a low survival rate and strong male bias. We studied the field cancerization in BLCA using multi-sample- and multi-tissue-per-patient protocol for sensitive detection of autosomal post-zygotic chromosomal alterations and loss of chromosome Y (LOY). We analysed 277 samples of histologically normal urothelium, 145 tumors and 63 blood samples from 52 males and 15 females, using the in-house adapted Mosaic Chromosomal Alterations (MoChA) pipeline.
View Article and Find Full Text PDFSynovial sarcoma is a relatively common soft tissue tumor characterized by highly specific t(X;18)(p11;q11) translocation resulting in the fusion of SS18 with members of SSX gene family. Typically, detection of SS18 locus rearrangement by fluorescence in situ hybridization or SS18 :: SSX fusion transcripts confirms the diagnosis. More recently, immunohistochemistry (IHC) for SS18-SSX chimeric protein (E9X9V) and C-terminus of SSX (E5A2C) showed high specificity and sensitivity for synovial sarcoma.
View Article and Find Full Text PDFVemurafenib and dabrafenib are BRAF kinase inhibitors (BRAFi) used for the treatment of patients with melanoma carrying the V600E BRAF mutation. However, melanoma cells develop resistance to both drugs when used as monotherapy. Therefore, mechanisms of drug resistance are investigated, and new molecular targets are sought that could completely inhibit melanoma progression.
View Article and Find Full Text PDFArticle Synopsis
- Melanoma is a tough skin cancer that often outsmarts the immune system, but immune checkpoint inhibitors (ICIs) like anti-PD1 can help reactivate immune responses against it.
- Despite the potential of ICIs, only a small number of patients respond effectively, with unclear reasons for resistance in others.
- This study analyzed melanoma tissues from patients before anti-PD1 treatment, finding that responders had higher immune scores and a greater presence of beneficial immune cells compared to non-responders, along with differences in gene expression patterns related to cancer aggressiveness.